Tyrosine kinase inhibitor treatment outcome in a single center cohort of chronic myeloid leukemia patients. The role of the T315I ABL kinase domain mutation
, , , , , e
08 ago 2013
INFORMAZIONI SU QUESTO ARTICOLO